Tirzepatide vs Retatrutide:
Which is Right for You?

Detailed comparison of Tirzepatide and Retatrutide — mechanisms, dosing, side effects, costs, and best use cases.

⚠️ Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any peptide or medication protocol.

Quick Comparison

FactorTirzepatideRetatrutide
CategoryGLP-1 / Weight LossGLP-1 / Weight Loss
Common Dose2,500–15,000 mcg4,000–12,000 mcg
FrequencyOnce weeklyOnce weekly
Half-Life~5 days~6 days
Best ForFDA-approved, proven safety profile, currently widely availableMaximum weight loss in clinical trials, Phase 3 trials ongoing

Tirzepatide

GLP-1 / Weight Loss

Tirzepatide (Mounjaro/Zepbound) is the first dual GIP/GLP-1 receptor agonist, producing superior weight loss vs semaglutide — averaging 20–22% body weight reduction in the SURMOUNT trials. By activating both GIP and GLP-1 receptors, it enhances insulin sensitivity, reduces appetite via dual hypothal...

Key Benefits

  • 20–22% average body weight reduction
  • Outperforms semaglutide in clinical trials
  • Dual GIP+GLP-1 mechanism
  • Improved insulin sensitivity

Dose: 2,500–15,000 mcg

Frequency: Once weekly

⚡ Tirzepatide Calculator

Retatrutide ★ Recommended

GLP-1 / Weight Loss

Retatrutide is a next-generation triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously — the most powerful weight loss compound in clinical development. Phase 2 trials by Eli Lilly demonstrated up to 24% body weight reduction, exceeding both semaglutide (~15%) and tirzepatide (~...

Key Benefits

  • Up to 24% body weight reduction in Phase 2
  • Triple receptor mechanism (GIP+GLP-1+Glucagon)
  • Superior energy expenditure and fat oxidation
  • Once-weekly dosing

Dose: 4,000–12,000 mcg

Frequency: Once weekly

⚡ Retatrutide Calculator

Which Should You Choose?

Retatrutide's triple mechanism (GIP+GLP-1+Glucagon) shows ~24% weight loss in Phase 2 vs tirzepatide's ~22%. However, retatrutide is not yet FDA-approved.

About Tirzepatide

Tirzepatide (Mounjaro/Zepbound) is the first dual GIP/GLP-1 receptor agonist, producing superior weight loss vs semaglutide — averaging 20–22% body weight reduction in the SURMOUNT trials. By activating both GIP and GLP-1 receptors, it enhances insulin sensitivity, reduces appetite via dual hypothalamic pathways, slows gastric emptying, and improves beta-cell function. FDA-approved for type 2 diabetes (Mounjaro) and weight management (Zepbound). Starting dose: 2.5 mg weekly, titrated every 4 weeks to 15 mg maximum. Track your tirzepatide titration schedule with the DoseIQ app.

📖 Read Full Tirzepatide Dosing Guide →

About Retatrutide

Retatrutide is a next-generation triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously — the most powerful weight loss compound in clinical development. Phase 2 trials by Eli Lilly demonstrated up to 24% body weight reduction, exceeding both semaglutide (~15%) and tirzepatide (~22%). Adding glucagon receptor activation further increases energy expenditure and fatty acid oxidation. Currently in Phase 3 trials; FDA approval expected 2026–2027. Compounded research versions available.

📖 Read Full Retatrutide Dosing Guide →

Frequently Asked Questions

Q: Is retatrutide better than tirzepatide?
A: Phase 2 data shows ~24% vs ~22% weight loss. Definitive Phase 3 head-to-head data pending.
Q: Is retatrutide FDA-approved?
A: Not as of 2026. Only compounded research peptide versions available.
Q: Which should I choose?
A: Tirzepatide is the safer choice with FDA approval. Retatrutide for those wanting maximum experimental weight loss.

📱 Track Every Dose with DoseIQ

The #1 peptide tracking app for iPhone. Calculate doses, log injections, set reminders, and track your progress.

⬇️ Download Free on App Store